EBC-1013: Our wound healing lead

EBC-1013 is a novel, semi-synthetic small molecule with a multifactorial mode of action that targets different phases of the wound healing process. The molecule is an analogue of our oncology drug tigilanol tiglate and its development programme leverages our already extensive preclinical and clinical knowledge of this unique drug class.

Our primary focus for EBC-1013 is in human clinical applications, but we also recognise the potential of the veterinary wound market, especially for treatment of horses.

Results from preclinical mode of action studies, and from treatment of veterinary clinical cases, suggest that the molecule has significant potential for use on a wide range of difficult to manage wounds, including chronic non-healing ulcers, traumatic acute wounds, infected wounds and burns. 

Our preliminary veterinary studies in these wound types show that EBC-1013 may impart significant benefits in both the speed and quality of healing by:

  1. Disrupting recalcitrant microbial biofilms which frequently impair healing;
  2. Stimulating migration and recolonisation of the wound bed by the surrounding dermal, epidermal and immune cells; and,
  3. Modifying the properties of the extracellular matrix in the remodelled wound bed resulting in good functionality and reduced scarring.